Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 161,709 | 141,148 | 120,856 | 108,185 | 83,879 |
| Cost of Goods | 28,093 | 18,938 | 15,541 | 15,400 | 9,341 |
| Gross Profit | 133,616 | 122,210 | 105,315 | 92,785 | 74,538 |
| Operating Expenses | 104,344 | 88,305 | 97,234 | 63,236 | 62,445 |
| Operating Income | 29,365 | 34,843 | 8,622 | 29,949 | 12,434 |
| Interest Expense | 6,721 | 6,716 | 6,757 | 6,931 | 10,832 |
| Other Income | 3,265 | 2,793 | 3,603 | 2,435 | 2,666 |
| Pre-tax Income | 25,909 | 30,920 | 5,468 | 25,453 | 4,268 |
| Income Tax | -364,986 | 2,733 | 408 | 2,122 | 388 |
| Net Income Continuous | 390,895 | 28,187 | 5,060 | 23,331 | 3,880 |
| Net Income | $390,895 | $28,187 | $5,060 | $23,331 | $3,880 |
| EPS Basic Total Ops | 2.69 | 0.19 | 0.03 | 0.15 | 0.03 |
| EPS Basic Continuous Ops | 2.69 | 0.19 | 0.03 | 0.16 | 0.03 |
| EPS Diluted Total Ops | 2.43 | 0.17 | 0.03 | 0.16 | 0.02 |
| EPS Diluted Continuous Ops | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 |
| EPS Diluted Before Non-Recurring Items | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 |
| EBITDA(a) | $28,945 | $33,923 | $7,646 | $28,617 | $11,095 |